Suppr超能文献

接受肿瘤整形性乳房缩小术和放射治疗的乳腺癌患者的局部复发模式。

Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammaplasty and radiotherapy.

作者信息

Eaton Bree R, Losken Albert, Okwan-Duodu Derick, Schuster David M, Switchenko Jeffrey M, Mister Donna, Godette Karen, Torres Mylin A

机构信息

Department of Radiation Oncology, Emory University, Atlanta, GA, USA,

出版信息

Ann Surg Oncol. 2014 Jan;21(1):93-9. doi: 10.1245/s10434-013-3235-8. Epub 2013 Oct 1.

Abstract

BACKGROUND

The purpose of this study was to describe the incidence and location of ipsilateral breast tumor recurrence (IBTR) among breast cancer patients treated with oncoplastic reduction mammoplasty (ORM) and radiotherapy (RT).

METHODS

The medical records of 86 consecutive women with ductal carcinoma in situ (DCIS) (n = 11) or invasive carcinoma of the breast (n = 75) treated with ORM at Emory University between January 1994 and December 2010 were reviewed.

RESULTS

Following ORM, prolonged wound healing or surgical complications led to delay of adjuvant chemotherapy or RT in 11 patients. Surgical clips were found outside the primary tumor breast quadrant in 43 % of the patients with available RT planning CT images. When the clips were found outside the primary tumor quadrant, the RT boost was more frequently delivered outside versus inside the primary tumor quadrant (67 vs. 33 %, p < 0.001). After a median follow-up period of 4.5 years (range 0.1-17.9), 6 patients developed an IBTR and only 1 IBTR occurred outside the primary tumor quadrant. The 5-year ipsilateral breast tumor control rates were 91 % (95 % CI 0.82-0.99) and 93 % (95 % CI 0.90-0.97) for patients with DCIS and invasive carcinoma, respectively.

CONCLUSIONS

The use of ORM yields acceptable rates of IBTR. ORM may displace breast tissue and surgical clips to breast quadrants outside of the original tumor location, but the majority of IBTRs still occur in the original tumor quadrant. This area remains at highest risk of in-breast recurrence in women treated with ORM irrespective of surgical clip location.

摘要

背景

本研究旨在描述接受肿瘤整形性乳房缩小术(ORM)和放射治疗(RT)的乳腺癌患者同侧乳腺肿瘤复发(IBTR)的发生率及部位。

方法

回顾了1994年1月至2010年12月在埃默里大学接受ORM治疗的86例连续的导管原位癌(DCIS)患者(n = 11)或浸润性乳腺癌患者(n = 75)的病历。

结果

ORM术后,11例患者出现伤口愈合延长或手术并发症,导致辅助化疗或RT延迟。在有RT计划CT图像的患者中,43%的患者手术夹位于原发肿瘤乳腺象限之外。当手术夹位于原发肿瘤象限之外时,RT瘤床加量更常施于原发肿瘤象限之外而非之内(67%对33%,p < 0.001)。中位随访期4.5年(范围0.1 - 17.9年)后,6例患者发生IBTR,仅1例IBTR发生在原发肿瘤象限之外。DCIS和浸润性癌患者的5年同侧乳腺肿瘤控制率分别为91%(95%CI 0.82 - 0.99)和93%(95%CI 0.90 - 0.97)。

结论

使用ORM可获得可接受的IBTR发生率。ORM可能会将乳腺组织和手术夹移位至原发肿瘤位置之外的乳腺象限,但大多数IBTR仍发生在原发肿瘤象限。无论手术夹位置如何,该区域仍是接受ORM治疗的女性乳腺内复发风险最高的部位。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验